and proteasome inhibitors has brought a major shift in therapeutic paradigm in the treatment of newly diagnosed and refractory multiple myeloma (MM). Thalidomide was the first immunomodulatory ...

Sarclisa plus Pd is approved for individuals with relapsed or refractory MM who have undergone two or more previous therapies, including lenalidomide and a proteasome inhibitor. This combination ...